



Characterization of recombinant human kidney diamine oxidase and equine plasma amine oxidase
by Bradley Owen Elmore

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy in Biochemistry
Montana State University
© Copyright by Bradley Owen Elmore (2002)

Abstract:

Human kidney diamine oxidase has been overexpressed as a secreted protein in *Drosophila* S2 cell culture. This represents the first heterologous overexpression and purification of a catalytically active, recombinant, mammalian copper-containing amine oxidase. To date, the direct examination of mammalian copper-containing amine oxidases has been difficult and limited, especially true for the human enzyme. The availability of large quantities of highly purified enzyme makes it now possible to investigate the spectroscopic, mechanistic, functional and structural properties of this human enzyme at the molecular level. Visible absorption, circular dichroism, electron paramagnetic resonance and resonance Raman spectroscopic results are presented. The recombinant enzyme contains the cofactors 2,4,5-trihydroxyphenylalanine quinone (TPQ) and copper at stoichiometries around 1.1 and 1.5 mol per mol homodimer, respectively. In addition, tightly bound and stoichiometric calcium ions were identified and are proposed to occupy the second metal binding site. Detailed kinetic studies indicate the preferred substrates are, in order, histamine, 1-methylhistamine, agmatine and putrescine. Inhibition by pharmaceutical compounds has been examined, and most notably, pentamidine has been demonstrated to be a competitive inhibitor with an inhibition constant in low nanomolar range. Azide is shown to be a competitive inhibitor against both substrate amine and dioxygen. Equine plasma copper-containing amine oxidase has also been purified from the natural source and characterized.

CHARACTERIZATION OF RECOMBINANT HUMAN KIDNEY
DIAMINE OXIDASE AND EQUINE PLASMA AMINE OXIDASE

by

Bradley Owen Elmore

A dissertation submitted in partial fulfillment
of the requirements for the degree

of

Doctor of Philosophy

in

Biochemistry

MONTANA STATE UNIVERSITY
Bozeman, Montana

October 2002


APPROVAL

of a dissertation submitted by

Bradley Owen Elmore

This dissertation has been read by each member of the dissertation committee and has been found to be satisfactory regarding content, English usage, format, citations, bibliographic style, and consistency, and is ready for submission to the College of Graduate Studies.


David M. Dooley


(Signature)

10.25.02
Date

Approved for the Department of Chemistry and Biochemistry


Paul A. Grieco


(Signature)

10-25-02
Date

Approved for the College of Graduate Studies

Bruce R. McLeod



(Signature)

10-29-02
Date

STATEMENT OF PERMISSION TO USE

In presenting this thesis in partial fulfillment of the requirements for a doctoral degree at Montana State University, I agree that the Library shall make it available to borrowers under rules of the Library. I further agree that copying of this dissertation is allowable only for scholarly purposes, consistent with "fair use" as prescribed in the U.S. Copyright Law. Requests for extensive copying or reproduction of this dissertation should be referred to Bell & Howell Information and Learning, 300 North Zeeb Road, Ann Arbor, Michigan 48106, to whom I have granted "the exclusive right to reproduce and distribute my dissertation in and from microform along with the non-exclusive right to reproduce and distribute my abstract in any format in whole or in part."

Signature

A handwritten signature in black ink, appearing to be "B. J. ...", written over a horizontal line.

Date

October 21, 2002

This thesis is dedicated to Nathan and Joshua Elmore,
who shared in my sacrifice and offered unconditional support, faith and love.

v
TABLE OF CONTENTS

	Page
1. INTRODUCTION.....	1
Post-translationally Modified Amino Acid Cofactors.....	1
Copper-containing Amine Oxidases.....	3
Structure.....	5
Mechanism.....	7
Mammalian Copper Amine Oxidases.....	11
Research Goals.....	13
2. EXPRESSION, PURIFICATION AND CHARACTERIZATION OF RECOMBINANT HUMAN KIDNEY DIAMINE OXIDASE.....	15
Introduction.....	15
Experimental Procedures.....	16
Construction of Cell Line.....	16
Expression.....	17
Purification.....	19
General Characterization.....	20
Tissue-Specific Gene Expression.....	21
Results.....	22
Expression and Purification.....	22
Electrophoresis and Analytical Ultracentrifugation.....	23
Copper, Calcium and TPQ.....	26
Tissue-Specific Expression.....	32
Discussion.....	34
Conclusions.....	41
3. STEADY STATE KINETICS AND SUBSTRATE PREFERENCE.....	43
Introduction.....	43
Experimental Procedures.....	48
Results.....	52
Discussion.....	63
Conclusions.....	71
4. DIAMINE OXIDASE AND HUMAN METABOLISM.....	72
Introduction.....	72
Histamine Metabolism.....	73
Agmatine.....	82
Putrescine and Polyamines.....	84

Conclusions.....	86
5. INHIBITION OF rhKDAO BY PHARMACEUTICALS.....	88
Introduction.....	88
Experimental Procedures.....	94
Results.....	95
Isoniazid.....	95
Cimetidine.....	96
Clonidine.....	99
Pentamidine.....	101
Berenil.....	103
Discussion.....	105
Isoniazid.....	105
Cimetidine.....	107
Clonidine.....	107
Pentamidine.....	107
Berenil.....	109
Conclusions.....	109
6. AZIDE INHIBITION OF rhKDAO.....	112
Introduction.....	112
Experimental Methods.....	113
Results.....	113
Azide and Putrescine Oxidation.....	113
Ionic Strength and Substrate Inhibition.....	116
Azide Inhibition of Dioxygen Reduction.....	118
Discussion.....	124
Conclusions.....	126
7. PURIFICATION AND CHARACTERIZATION OF EQUINE PLASMA AMINE OXIDASE.....	127
Introduction.....	127
Experimental Procedures.....	129
Purification.....	129
Analysis of EPAO.....	133
Results.....	134
EPAO Purification.....	134
Copper and Calcium.....	142
Visible and CD Spectroscopy.....	145
TPQ Quantitation.....	145
Resonance Raman Spectroscopy.....	148

Steady State Kinetics for Benzylamine Oxidation.....	149
Crystallization and Diffraction.....	150
Discussion.....	151
EPAO Purification.....	151
Copper, Calcium and TPQ.....	153
Visible Absorption, Circular Dichroism, EPR and Resonance Raman.....	154
Conclusions.....	155

APPENDICES

Appendix A – Amino acid sequence alignment.....	158
Appendix B – Generation of Phylogenetic Trees.....	201
Appendix C – Use of Gröbner Bases To Derive Steady State Rate Equations.....	221
REFERENCES CITED.....	242

viii
LIST OF TABLES

Table	Page
1. Purification of recombinant human kidney diamine oxidase.....	23
2. Metal ion and TPQ stoichiometry for recombinant human kidney diamine oxidase as isolated from three enzyme preparations.....	26
3. Steady-state kinetic parameters and substrate specificity (k_{cat}/K_M) for recombinant human kidney diamine oxidase.....	53
4. Summary of two EPAO purifications.....	141
5. Divalent metal and TPQ quantification for dimeric EPAO.....	143

LIST OF FIGURES

Figure	Page
1. Post-translationally modified quinone cofactors.....	2
2. TPQ resonance structures.....	4
3. Phylogenetic tree for the copper amine oxidases.....	4
4. Structure of the ECAO homodimer.....	6
5. The active site of PSAO.....	7
6. Proposed reaction mechanism for the oxidation of amines by copper-containing amine oxidases.....	9
7. Schematic of the Expression of hKDAO in <i>Drosophila</i> S2 cells.....	18
8. SDS/PAGE showing purification of recombinant human kidney diamine oxidase.....	24
9. X-band EPR spectrum of rhKDAO.....	28
10. Absorption Spectrum of the purified recombinant human kidney diamine oxidase.....	29
11. Circular dichroism spectrum of rhKDAO.....	29
12. Phenylhydrazine titration of TPQ in purified rhKDAO.....	30
13. Resonance Raman spectrum of the phenylhydrazine-derivatized human rhKDAO.....	31
14. Multiple human tissue expression array with polyA mRNA from 76 tissues and cell lines.....	33
15. View of the copper and second metal binding sites form pea seedling amine oxidase.....	39
16. Structure of exogenous aromatic amine substrates for copper amine oxidases.....	44
17. Structures of aliphatic diamines and polyamines.....	45

18. Structures of histamine and 1-methylhistamine.....	46
19. Structures of derivatives of the amino acids lysine, arginine and tyrosine.....	47
20. Mechanistic models used to derive enzyme rate equations.....	50
21. Histamine fit to the substrate inhibition model.....	54
22. Histamine fit to the substrate inhibition at two enzyme forms.....	55
23. Histamine fit to the substrate inhibition model plus an additional Michaelis-Menten model.....	55
24. 1-methylhistamine fit to the Michaelis-Menten model.....	56
25. Agmatine fit to the substrate inhibition model.....	56
26. Agmatine fit to the substrate inhibition model plus an additional Michaelis-Menten model.....	57
27. Putrescine fit to the substrate inhibition model.....	57
28. Cadaverine fit to the Michaelis-Menten model.....	58
29. DAB fit to the Michaelis-Menten model.....	58
30. 1,3-Diaminopropane fit to the Michaelis-Menten model.....	59
31. 1,6-Diaminohexane fit to the Michaelis-Menten model.....	59
32. 2-Aminoethylamine fit to the Michaelis-Menten model.....	60
33. Spermine fit to the Michaelis-Menten model.....	60
34. L-lysine methyl ester fit to the Michaelis-Menten model.....	61
35. pH dependence of steady state kinetic parameters for putrescine and rhKDAO.....	62
36. Histamine binding in nitrophorin, histamine binding protein and human histamine methyltransferase.....	70
37. Isonizid.....	90

38. Structure of cimetidine.....	91
39. Structure of clonidine.....	92
40. Structure of pentamidine.....	93
41. Structure of berenil.....	93
42. Isoniazid inhibition plot of initial reaction velocity against substrate putrescine concentration.....	95
43. Lineweaver-Burk plot for isoniazid inhibition.....	96
44. Cimetidine inhibition plots.....	97
45. Inhibition plot at 0, 50 and 100 μM isoniazid.....	98
46. Lineweaver-Burk plot for cimetidine.....	98
47. Cimetidine K_i determination.....	99
48. Inhibition plot for clonidine at 100, 250, 500 and 1000 μM	100
49. Lineweaver-Burk plot for clonidine.....	100
50. K_i determination for clonidine.....	101
51. Inhibition plot for pentamidine at 250, 500 and 1000 nM.....	102
52. Lineweaver-Burk plot for pentamidine.....	102
53. K_i determination for pentamidine.....	103
54. Inhibition plot for berenil at 0, 125 and 250 nM.....	104
55. Lineweaver-Burk plot for berenil.....	104
56. K_i determination for berenil.....	105
57. Azide inhibition of putrescine oxidation.....	114
58. Lineweaver-Burk plot for azide and putrescine oxidation.....	115

59. Azide K_i determination for putrescine oxidation.....	115
60. Ionic strength effect on the oxidation of putrescine.....	117
61. Rates of dioxygen consumption at 25 mM azide.....	118
62. Rates of dioxygen consumption at 50 mM azide.....	119
63. Rates of dioxygen consumption at 100 mM azide.....	119
64. Rates of dioxygen consumption at 200 mM azide.....	120
65. Lineweaver-Burk plot of azide inhibition.....	121
66. K_i determination for azide inhibition of dioxygen reduction.....	121
67. Azide titration of rhKDAO.....	123
68. Azide titration curve of rhKDAO.....	123
69. Anion exchange chromatography with a HiLOAD 26/10 Q-Sepharose HP column.....	136
70. Anion exchange chromatography with a HiLOAD 26/10 Q-Sepharose HP column showing EPAO activity.....	137
71. Chromatogram of gel filtration on a 1.6 x 100 cm Ultrogel Aca34 column.....	138
72. SDS/PAGE of the purification for EPAO.....	139
73. Native PAGE.....	140
74. IEF gel.....	140
75. EPR spectrum of 46.8 μ M EPAO in 100 mM K_p , pH 7.1.....	144
76. Visible absorption spectrum of oxidized form of EPAO (14 mg/ml).....	146
77. Visible absorption spectrum of the anaerobically substrate reduced equine plasma amine oxidase.....	146
78. Circular dichroism spectrum of equine plasma amine oxidase.....	147

79. Phenylhydrazine titration of EPAO.....	147
80. Resonance Raman spectrum of the phenylhydrazine derivatives of EPAO...	148
81. Resonance Raman spectrum of native EPAO.....	149
82. Steady state kinetics of benzylamine oxidation by EPAO.....	150

ABSTRACT

Human kidney diamine oxidase has been overexpressed as a secreted protein in *Drosophila* S2 cell culture. This represents the first heterologous overexpression and purification of a catalytically active, recombinant, mammalian copper-containing amine oxidase. To date, the direct examination of mammalian copper-containing amine oxidases has been difficult and limited, especially true for the human enzyme. The availability of large quantities of highly purified enzyme makes it now possible to investigate the spectroscopic, mechanistic, functional and structural properties of this human enzyme at the molecular level. Visible absorption, circular dichroism, electron paramagnetic resonance and resonance Raman spectroscopic results are presented. The recombinant enzyme contains the cofactors 2,4,5-trihydroxyphenylalanine quinone (TPQ) and copper at stoichiometries around 1.1 and 1.5 mol per mol homodimer, respectively. In addition, tightly bound and stoichiometric calcium ions were identified and are proposed to occupy the second metal binding site. Detailed kinetic studies indicate the preferred substrates are, in order, histamine, 1-methylhistamine, agmatine and putrescine. Inhibition by pharmaceutical compounds has been examined, and most notably, pentamidine has been demonstrated to be a competitive inhibitor with an inhibition constant in low nanomolar range. Azide is shown to be a competitive inhibitor against both substrate amine and dioxygen. Equine plasma copper-containing amine oxidase has also been purified from the natural source and characterized.

INTRODUCTION

Post-Translationally Modified Amino Acid Cofactors

Biological systems have developed the means to substantially extend the chemical properties and thus functionality of the twenty common amino acids that make up proteins via chemical modification. A special case is the post-translationally modified amino acids that serve as cofactors in enzyme catalysis and thus supplement the "normal" complement of enzyme cofactors and prosthetic groups, such as NAD(H), flavins, pyridoxal phosphate, Fe-heme groups, metal ions, etc.

This recently discovered group of enzymes requires the post-translational modification of an intrinsic, encoded amino acid residue for catalytic activity. The number of these modified cofactors, currently 19, will likely soon outnumber the naturally occurring amino acids used in protein biosynthesis. This group of enzymes has representatives in every branch of life and includes enzymes of fundamental importance to life on earth. For example, cytochrome c oxidase, the terminal oxidase of the electron transport chain, contains a tyrosine cross-linked to a histidine ligand of Cu_B . Ribulose-1,5-bisphosphate carboxylase (rubisco), responsible for the first step of photosynthetic CO_2 fixation, contains a carbamylated lysine residue that ligates a magnesium ion. A recent review is by Okeley and Van der Donk [1].

A sub-group of post-translationally modified amino acid cofactors is comprised of those that contain a quinone cofactor (Figure 1). TPQ, 2,4-trihydroxyphenylalanine quinone, is the organic tyrosine derived cofactor in the copper containing amine oxidases

(EC 1.4.3.6). LTQ, lysyl tyrosylquinone, is found in the copper containing lysyl oxidases (EC 1.4.3.13), which oxidize peptidyl lysine residues for cross-linking of elastin and collagen in connective tissue. Tryptophan tyrtrophylquinone (TTQ), an oxidized cross-link between two tryptophans is present in bacterial methylamine dehydrogenase (EC 1.4.99.3). CTQ, cysteine tryptophyl quinone, is a very recent addition to this group and is formed from the oxidation of a cross-linked cysteine and tryptophan in the bacterial quinohemoprotein amine dehydrogenase.




Figure 1. Post-translationally modified quinone cofactors; **A)** 2,4-trihydroxyphenylalanine quinone, TPQ; **B)** lysyl tyrosylquinone, LTQ; **C)** tryptophan tyrtrophylquinone, TTQ; **D)** cysteine tryptophyl quinone, CTQ

Copper Containing Amine Oxidases

The TPQ containing enzymes, copper containing amine oxidases (CAOs) are the focus of this thesis. There is another distinct class of enzymes referred to as amine oxidase, monoamine oxidase, tyramine oxidase, adrenalin oxidase, or polyamine oxidase. This latter group, EC 1.4.3.4, contains a flavin cofactor and will not be discussed herein.

CAO's are homodimers, generally ranging in size from 140 to 200 kDa, with one active site found in each monomer [2]. Each active site contains two cofactors: 1) a single Type II copper ion, and 2) TPQ. The quinone cofactor is derived from the post-translational modification of an invariant tyrosine residue [3]. TPQ has been shown to be produced in a novel, self-processing reaction requiring only copper and dioxygen [4-7]. CAOs are unique in that they are homodimeric, contain one organic and one inorganic cofactor in each of two active sites, and the organic cofactor is a quinone from the autocatalytic oxidation of an intrinsic tyrosine.

TPQ containing enzymes are pink in color, with a broad absorption feature around 480 nm attributed to the quinone cofactor. In the active enzyme, TPQ is an oxoanion [8]. Resonance Raman spectra indicate the charge is delocalized over the C2 and C4 oxygens (Figure 2) [9]. Differences in the TPQ λ_{\max} values among CAOs from different sources are thought to reflect the degree of charge localization [10].




Figure 2. TPQ resonance structures




Figure 3. Phylogenetic tree for the copper amine oxidases

CAOs are widespread in nature, having been described from gram-positive and gram-negative bacteria, yeast and fungi, plants and animals [2]. Recently the gene encoding a copper amine oxidase has been sequenced from the archaea *Solfolobus solfataricus*. Figure 3 shows a phylogenetic tree constructed for the family of copper containing amine oxidases, see Appendix B for details. An alignment of the amino acid sequences for all CAOs sequenced to date is given in Appendix A.

Structure

The structures of four copper amine oxidases have been solved by x-ray crystallography: two are bacterial (*Escherichia coli* and *Arthrobacter globiformis*), one is from the yeast *Hansenula polymorpha* (formally classified as *Pichia angusta*), and one is from pea seedling (*Pisum sativum*) [11-14]. Collectively these four enzymes exhibit considerable structural homology, although primary sequence identity is less than 40% between any two. The enzymes are "mushroom" shaped with an extensive intersubunit contact, including a pair of "arms" extending from each subunit to embrace the other. Figure 4 shows the ribbon structure of the *Escherichia coli* copper amine oxidase (ECAO). Each monomer is comprised of four domains. The N-terminal domain (D1) forms the "stalk" portion of the "mushroom" and is not present in all copper amine oxidases. A large (440-amino acid) β -sandwich C-terminal domain contains the active site and forms the majority of the dimer interface. Domains D2 and D3 have remarkably similar folds, an α -helix and a four-stranded antiparallel β -sheet. A channel for substrate access and product exit lies between domains D3 and D4.

